Maxigen Biotech Inc. Sustainability Profile
Maxigen Biotech Inc., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia and beyond. Founded in 2000, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced diagnostic solutions. Specialising in the production of recombinant proteins, monoclonal antibodies, and cell culture products, Maxigen Biotech stands out for its commitment to quality and cutting-edge technology. The company’s unique offerings cater to various industries, including pharmaceuticals, diagnostics, and research. With a strong market position, Maxigen Biotech has achieved significant milestones, including collaborations with major research institutions and a robust portfolio of patented technologies. This dedication to innovation and excellence has solidified its reputation as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Maxigen Biotech Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Maxigen Biotech Inc.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Maxigen Biotech Inc.'s reported carbon emissions
Maxigen Biotech Inc., headquartered in Taiwan (TW), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). This lack of data suggests that Maxigen Biotech Inc. may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the industry increasingly prioritises sustainability, it is essential for Maxigen Biotech Inc. to consider setting measurable climate commitments and reduction targets to align with global efforts in combating climate change.
How Carbon Intensive is Maxigen Biotech Inc.'s Industry?
How Carbon Intensive is Maxigen Biotech Inc.'s Location?
Maxigen Biotech Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Maxigen Biotech Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
